RSV, Canada and Moderna
Canada approves Moderna's RSV vaccine for those age 60 and older, company says
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus, or RSV, in adults 60 years and older, making it the country's first authorized mRNA-based shot for the condition. Health Canada has approved the ...
Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...
Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...
Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...
Moderna delivered better-than-expected profit and sales in the third quarter after an early start to sales of this season’s ...
Moderna on Thursday posted a surprise profit for the third quarter, smashing Wall Street estimates, as its cost-cutting efforts took hold and sales of its Covid vaccine came in higher than expected.
While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...
Moderna chief executive officer Stéphane Bancel steps down as chief commercial officer, with president Stephen Hoge assuming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback